Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by State of Wyoming

State of Wyoming increased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 357.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 12,360 shares of the biotechnology company’s stock after buying an additional 9,658 shares during the period. State of Wyoming’s holdings in Exelixis were worth $412,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. MassMutual Private Wealth & Trust FSB lifted its holdings in Exelixis by 18.1% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 290 shares during the period. Balyasny Asset Management L.P. raised its position in shares of Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock worth $573,000 after buying an additional 317 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in shares of Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 330 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in shares of Exelixis by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after acquiring an additional 354 shares in the last quarter. Finally, Principal Securities Inc. boosted its holdings in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Performance

Shares of NASDAQ:EXEL opened at $44.36 on Wednesday. The company has a market cap of $12.10 billion, a PE ratio of 25.06, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $48.85. The firm has a 50 day simple moving average of $37.54 and a 200 day simple moving average of $35.97.

Analyst Upgrades and Downgrades

EXEL has been the topic of several recent analyst reports. Citigroup boosted their target price on Exelixis from $45.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, May 15th. Truist Financial boosted their price objective on Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. UBS Group restated an “underperform” rating on shares of Exelixis in a report on Thursday, April 17th. StockNews.com lowered Exelixis from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 15th. Finally, Piper Sandler boosted their price target on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.94.

Insiders Place Their Bets

In other news, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the sale, the executive vice president now owns 303,310 shares in the company, valued at $11,216,403.80. This represents a 14.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the transaction, the chief financial officer now owns 779,607 shares in the company, valued at $28,174,996.98. This represents a 3.62% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 520,942 shares of company stock worth $22,930,002. Corporate insiders own 2.82% of the company’s stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.